GlaxoSmithKline Licenses SkyePharma Formulation Technology for Respiratory Drugs LONDON, Jan. 5, 2004 (PRIMEZONE) -- SkyePharma PLC (LSE:SKP) (Nasdaq:SKYE) today announced a licence agreement with GlaxoSmithKline (LSE:GSK) (NYSE:GSK) to provide access to one of SkyePharma's...

SkyePharma PLC Provides End-2003 Trading Update LONDON, Jan. 5, 2004 (PRIMEZONE) -- SkyePharma PLC (Nasdaq:SKYE) (LSE:SKP) announces a Trading Update for the year ending 31 December 2003. As a result of delays in concluding a number of key deals...

SkyePharma Welcomes FDA Approval of Additional Indication for Paxil CR LONDON, Oct. 20, 2003 (PRIMEZONE) -- SkyePharma PLC (Nasdaq:SKYE) (LSE:SKP) welcomes the recent announcement by its partner GlaxoSmithKline (NYSE:GSK), that the US Food & Drug Administration...

SkyePharma PLC -- Director Shareholding LONDON, Oct. 17, 2003 (PRIMEZONE) -- SkyePharma PLC ("the Company") (Nasdaq:SKYE) (LSE:SKP): As previously disclosed in the Company's Annual Report 2002, Mr Gowrie-Smith, Executive Chairman, had...

SkyePharma Preliminary Results Presentation LONDON, April 10, 2002 (PRIMEZONE) -- SkyePharma plc (Nasdaq:SKYE): Log on to www.cantos.com to watch Michael Ashton (CEO) and Donald Nicholson (CFO) give their presentation and discuss: -...